Patents by Inventor Tien T. Duong

Tien T. Duong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treatment with compounds having RAR alpha receptor specific or selective activity
    Publication number: 20020077360
    Abstract: Retinoid compounds which act specifically or selectively on RAR&agr; receptor subtypes in preference over RAR&bgr; and RAR&Ggr; receptor subtypes, posses desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenecity.
    Type: Application
    Filed: November 29, 2001
    Publication date: June 20, 2002
    Applicant: Allergan Sales, Inc.
    Inventors: Min Teng, Tien T. Duong, Roshantha A. Chandraratna
  • ACETYLENES DISUBSTITUTED WITH A 5 ALKYL, ARYL OR HETEROARYL SUBSTITUTED DIHYDRONAPHTHYL GROUP AND WITH AN ARYL OR HETEROARYL GROUP HAVING RETINOID-LIKE WITH AN ARYL OR HETEROARYL GROUP HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY
    Patent number: 6355806
    Abstract: Compounds of the formula wherein the symbols have the meaning described in the specification, have retinoid-like biological activity.
    Type: Grant
    Filed: September 16, 1999
    Date of Patent: March 12, 2002
    Assignee: Allergen Sales, Inc.
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thichroman and 1,2,3,4-tetrahydroquinolinecarboxlic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
    Patent number: 6342602
    Abstract: Compounds of the formula wherein the symbols have the meaning defined in the specification have retinoid-like biological activity.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: January 29, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Min Teng, Tien T. Duong, Roshantha A. Chandraratna
  • Substituted aryl or heteroarylamides having retinoid-like biological activity
    Patent number: 6320047
    Abstract: Compounds of the formula wherein the symbols have the meaning described in the specification, have retinoid-like biological activity.
    Type: Grant
    Filed: April 9, 2001
    Date of Patent: November 20, 2001
    Assignee: Allergan Sales, Inc.
    Inventors: Min Teng, Tien T. Duong, Roshantha A. Chandraratna
  • Substituted aryl or heteroarylamides having retinoid-like biological activity
    Patent number: 6245786
    Abstract: Compounds of the formula wherein the symbols have the meaning described in the specification, have retinoid-like biological activity.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: June 12, 2001
    Assignee: Allergan Sales, Inc.
    Inventors: Min Teng, Tien T. Duong, Roshantha A. Chandraratna
  • Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
    Patent number: 6228848
    Abstract: Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: May 8, 2001
    Assignee: Allergan, Inc.
    Inventors: Elliott S. Klein, Alan T. Johnson, Andrew M. Standeven, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Sunil Nagpal, Vidyasagar Vuligonda, Min Teng, Roshantha A. Chandraratna
  • Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
    Patent number: 6124455
    Abstract: Compounds of the formula ##STR1## wherein the symbols have the meaning defined in the specification have retinoid-like biological activity.
    Type: Grant
    Filed: January 25, 2000
    Date of Patent: September 26, 2000
    Assignee: Allergan Sales, Inc.
    Inventors: Min Teng, Tien T. Duong, Roshantha A. Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist like biological activity
    Patent number: 6117987
    Abstract: Compounds of the formula ##STR1## where the symbols have the meaning describedin the application, have retinoid-like or retinoid antagonist-like biological activity.
    Type: Grant
    Filed: April 8, 1998
    Date of Patent: September 12, 2000
    Assignee: Allergan Sales, Inc.
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
    Patent number: 6090810
    Abstract: Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: July 18, 2000
    Assignee: Allergan Sales, Inc.
    Inventors: Elliott S. Klein, Alan T. Johnson, Andrew M. Standeven, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Sunil Nagpal, Vidyasagar Vuligonda, Min Teng, Roshantha A. Chandraratna
  • Substituted aryl or heteroarylamides having retinoid-like biological activity
    Patent number: 6051713
    Abstract: Compounds of the formula ##STR1## wherein the symbols have the meaning described in the specification, have retinoid-like biological activity.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: April 18, 2000
    Assignee: Allergan Sales, Inc.
    Inventors: Min Teng, Tien T. Duong, Roshantha A. Chandraratna
  • Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
    Patent number: 6034244
    Abstract: Compounds of the formula ##STR1## wherein the symbols have the meaning defined in the specification, have retinoid-like biological activity.
    Type: Grant
    Filed: October 15, 1998
    Date of Patent: March 7, 2000
    Assignee: Allergan Sales, Inc.
    Inventors: Min Teng, Tien T. Duong, Roshantha A. Chandraratna
  • Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
    Patent number: 6008204
    Abstract: Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: December 28, 1999
    Assignee: Allergan Sales, Inc.
    Inventors: Elliott S. Klein, Alan T. Johnson, Andrew M. Standeven, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Sunil Nagpal, Vidyasagar Vuligonda, Min Teng, Roshantha A. Chandraratna
  • Alkylidene substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Patent number: 5998655
    Abstract: Compounds of the formula ##STR1## where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.
    Type: Grant
    Filed: February 25, 1998
    Date of Patent: December 7, 1999
    Inventors: Vidyasagar Vuligonda, Min Teng, Richard L. Beard, Alan T. Johnson, Tien T. Duong, Yuan Lin, Roshantha A. Chandraratna
  • Acetylenes disubstituted with a 5 alkyl, aryl or heteroaryl substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
    Patent number: 5998471
    Abstract: Compounds of the formula ##STR1## the symbols have the meaning described in the specification.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: December 7, 1999
    Assignee: Allergan Sales, Inc.
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Methods of treatment with compounds having RAR.sub..alpha. receptor specific or selective activity
    Patent number: 5965606
    Abstract: Retinoid compounds which act specifically or selectively on RAR.sub..alpha. receptor subtypes in preference over RAR.sub..beta. and RAR.sub..gamma. receptor subtypes, posses desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenecity.
    Type: Grant
    Filed: December 29, 1995
    Date of Patent: October 12, 1999
    Assignee: Allergan Sales, Inc.
    Inventors: Min Teng, Tien T. Duong, Roshantha A. Chandraratna
  • Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
    Patent number: 5958954
    Abstract: 2,2-Dialkyl-4-aryl-substituted benzopyran and benzothiopyran derivatives of the formula ##STR1## where the symbols have the meaning described in the specification, have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists.
    Type: Grant
    Filed: December 24, 1997
    Date of Patent: September 28, 1999
    Assignee: Allergan Sales, Inc.
    Inventors: Elliott S. Klein, Alan T. Johnson, Andrew M. Standeven, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Sunil Nagpal, Vidyasagar Vuligonda, Min Teng, Roshantha A. Chandraratna
  • Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
    Patent number: 5952345
    Abstract: Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: September 14, 1999
    Assignee: Allergan Sales, Inc.
    Inventors: Elliot S. Klein, Alan T. Johnson, Andrew M. Standeven, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Sunil Nagpal, Vidyasagar Vuligonda, Min Teng, Roshantha A. Chandraratna
  • Substituted aryl or heteroarylamides having retinoid-like biological activity
    Patent number: 5917048
    Abstract: Compounds of the formula ##STR1## wherein the symbols have the meaning described in the specification, have retinoid-like biological activity.
    Type: Grant
    Filed: March 19, 1997
    Date of Patent: June 29, 1999
    Assignee: Allergan Sales Inc.
    Inventors: Min Teng, Tien T. Duong, Roshantha A. Chandraratna
  • Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
    Patent number: 5877207
    Abstract: Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.
    Type: Grant
    Filed: June 24, 1997
    Date of Patent: March 2, 1999
    Assignee: Allergan Sales, Inc.
    Inventors: Elliott S. Klein, Alan T. Johnson, Andrew M. Standeven, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Sunil Nagpal, Vidyasagar Vuligonda, Min Teng, Roshantha A. Chandraratna
  • Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
    Patent number: 5856490
    Abstract: Compounds of the formula ##STR1## where the symbols have the meaning defined in the specification have retinoid-like biological activity.
    Type: Grant
    Filed: September 4, 1997
    Date of Patent: January 5, 1999
    Assignee: Allergan
    Inventors: Min Teng, Tien T. Duong, Roshantha A. Chandraratna